DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER).
Intraperitoneal administration of Dianeal PD-1 with 4.25% dextrose creates an osmotic gradient across the peritoneal membrane, promoting ultrafiltration of fluid and removal of uremic solutes (e.g., urea, creatinine) through diffusion and convection.
| Metabolism | Dextrose is absorbed from the peritoneal cavity into the systemic circulation and metabolized via glycolysis and oxidative phosphorylation. Insulin may be required in diabetic patients due to dextrose absorption. |
| Excretion | Dextrose is metabolized to CO2 and water; less than 1% excreted unchanged in urine. No biliary/fecal elimination. |
| Half-life | Not applicable; dextrose is continuously absorbed and metabolized; elimination half-life depends on glucose utilization rate (2-4 hours in normal state). |
| Protein binding | <1% (dextrose not protein-bound). |
| Volume of Distribution | Approximately 0.2 L/kg (dextrose distributes to total body water). |
| Bioavailability | Intraperitoneal: 100% (dextrose absorbed systemically). |
| Onset of Action | Intraperitoneal: Ultrafiltration begins within 10-15 minutes; peak effect at 60-120 minutes. |
| Duration of Action | Intraperitoneal: Dwell time 4-6 hours for standard exchanges; net fluid removal continues until osmotic gradient dissipates. |
Intraperitoneal administration; dose individualized based on body size, residual renal function, and dialysis adequacy. Typical regimen: 2-2.5 L instilled into peritoneal cavity for a dwell time of 4-8 hours, 4-5 exchanges per day in continuous ambulatory peritoneal dialysis (CAPD).
| Dosage form | SOLUTION |
| Renal impairment | Not applicable; this product is used as replacement therapy for renal failure and pharmacokinetics are not dependent on GFR. |
| Liver impairment | No dose adjustment recommended; pharmacokinetics of peritoneal dialysis solutions are not affected by hepatic function. |
| Pediatric use | Intraperitoneal administration; dosing based on body surface area (BSA) or weight. Typical starting volume: 800-1000 mL/m² per exchange (or 30-40 mL/kg) with dwell times of 4-6 hours, 4-5 exchanges per day in CAPD. Adjust based on adequacy and tolerance. |
| Geriatric use | No specific dose adjustment; use standard dosing but monitor for increased risk of peritonitis and fluid/electrolyte imbalances due to age-related changes in peritoneal membrane function and renal reserve. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER (DIANEAL PD-1 W/ DEXTROSE 4.25% IN PLASTIC CONTAINER).
| Breastfeeding | Dextrose is a normal component of breast milk. After intraperitoneal administration, systemic absorption of dextrose is limited and rapid metabolism occurs. Excretion into breast milk is negligible. Therefore, Dianeal PD-1 with dextrose 4.25% is considered compatible with breastfeeding. The milk-to-plasma ratio is not applicable due to minimal systemic levels. |
| Teratogenic Risk | Dianeal PD-1 with 4.25% dextrose is a peritoneal dialysis solution. Dextrose is a normal constituent of the body and is not teratogenic at therapeutic doses. However, maternal metabolic disturbances such as hyperglycemia from high dextrose loads may pose risks to the fetus, including macrosomia and neonatal hypoglycemia, particularly in the second and third trimesters. No dedicated teratogenicity studies exist for this specific preparation. |
■ FDA Black Box Warning
Not for intravenous use. Peritoneal dialysis may cause peritonitis, catheter exit-site infections, and other complications. Use strict aseptic technique.
| Serious Effects |
["Pre-existing severe hyperglycemia or diabetic ketoacidosis","Documented hypersensitivity to dextrose or components","Abdominal conditions: Recent abdominal surgery, extensive adhesions, abdominal wall infections, bowel obstruction, diaphragmatic defects","Severe respiratory insufficiency with high intra-abdominal pressure","Chronic or recurrent peritonitis"]
| Precautions | ["Peritonitis: Risk of infection; monitor for cloudy effluent, abdominal pain, fever","Catheter complications: Exit-site/tunnel infections, leakage, obstruction","Metabolic complications: Hyperglycemia, hypertriglyceridemia, weight gain","Fluid/electrolyte imbalances: Hypovolemia, hypernatremia, hypokalemia","Inadequate dialysis: Monitor urea clearance"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum glucose and electrolyte levels (sodium, potassium, chloride, bicarbonate) regularly. Watch for signs of peritonitis, dehydration, or fluid overload. Perform fetal monitoring as per standard pregnancy care; no specific additional monitoring required. |
| Fertility Effects | No known adverse effects on fertility. The solution itself is not expected to impair reproductive function. However, underlying renal disease may affect fertility. |